Tiefenbacher Pharmaceuticals: Launch of first generic version of the antihistamine Bilastine

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited to share that we have successfully launched the first generic version of Bilastine (20 mg tablets) in Spain. Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms, such as hay fever and urticaria. The second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis (like sneezing and red, streaming eyes) as well as urticaria caused symptoms (like itchy skin). With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment. Following our global market entry approach, a launch in several further international countries is already in preparation.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on: www.tiefenbacher-pharmaceuticals.com